Dunming J. Xiao

130 Dongan Rd
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China.

Budget impact analysis of aztreonam-avibactam for metallo-β-lactamase carbapenem-resistant enterobacterales infections in China.

Journal: Infection

Published: January 21, 2026

Economic evaluation of bulk packaging and single-dose packaging of contrast media for contrast-enhanced CT.

Economic evaluation of bulk packaging and single-dose packaging of contrast media for contrast-enhanced CT.

Journal: European journal of radiology

Published: September 24, 2025

Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand.

Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand.

Journal: Health economics review

Published: March 10, 2025

Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective.

Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: January 08, 2025

Therapeutic applications of drug coated balloons in symptomatic intracranial arterial stenosis: systematic review and quantitative meta-analysis.

Therapeutic applications of drug coated balloons in symptomatic intracranial arterial stenosis: systematic review and quantitative meta-analysis.

Journal: Journal of neurointerventional surgery

Published: December 12, 2024

Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.

Economic evaluation of treating invasive aspergillosis with isavuconazole, posaconazole and voriconazole in China.

Journal: Future microbiology

Published: November 18, 2024

Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation.

Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation.

Journal: Clinical therapeutics

Published: November 03, 2024

Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma.

Cost-effectiveness of first-line systemic therapies for unresectable hepatocellular carcinoma.

Journal: British journal of clinical pharmacology

Published: September 30, 2024

Correction to: Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population.

Correction to: Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population.

Journal: Advances in therapy

Published: September 25, 2024

Cost-effectiveness analysis of tandem mass spectrometry compared to fluorescence analysis for screening neonatal genetic metabolic diseases.

Cost-effectiveness analysis of tandem mass spectrometry compared to fluorescence analysis for screening neonatal genetic metabolic diseases.

Journal: BMC health services research

Published: September 01, 2024

Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting.

Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting.

Journal: Diabetology & metabolic syndrome

Published: July 11, 2024

Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.

Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.

Journal: PloS one

Published: April 06, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026